Khiron Life Sciences Receives Authorization For The Sale Of High-CBD Medical Cannabis In Peru – The Deep Dive

Khiron Life Sciences (TSXV: KHRN) announced this morning that it now has access to yet another medical cannabis market: Peru. Khiron has received all required licenses and authorizations for the import and commercialization of full spectrum, high-CBD medical cannabis productions.

The products will be imported to Peru from that of Khiron Colombia, with the product then being manufactured and distributed to patients within the country by that of Farmacia Universal under a previously announced arrangement.

While currently approved for the import and sale of full spectrum high-CBD medical cannabis products, Khiron is also working towards receiving approvals from the Directorate General of Drug Supplies and Drugs (DIGEMID), the governing body in Peru, for the import and commercialization of high-THC medical cannabis products. The company currently anticipates this approval to be received in the fourth quarter of 2020.

"Entry to the Peru medical cannabis market continues our relentless focus on meeting patient needs in Latin America and globally. We are currently the only company in Colombia that has dispensed medical cannabis to patients and have now surpassed our first 1,000 medical cannabis patient prescriptions milestone. This, despite a global pandemic that has slowed down many of the world's economies, represents a very important achievement for us." Alvaro Torres, CEO of Khiron

With these authorizations, Khiron Peru is now able to begin importing high-CBD product from that of Khiron Colombia. The
Source…